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Ceftobiprole medocaril is a newly approved drug in Europe for the treatment of hospital-acquired pneumonia (HAP) (excluding
patients with ventilator-associated pneumonia but including ventilated HAP patients) and community-acquired pneumonia in
adults. The aim of this study was to evaluate the in vitro antimicrobial activity of ceftobiprole against prevalent Gram-positive
and -negative pathogens isolated in Europe, Turkey, and Israel during 2005 through 2010. A total of 60,084 consecutive, nondu-
plicate isolates from a wide variety of infections were collected from 33medical centers. Species identification was confirmed,
and all isolates were susceptibility tested using reference broth microdilutionmethods. Ceftobiprole had high activity against
methicillin-susceptible Staphylococcus aureus (MSSA) (100.0% susceptible), methicillin-susceptible coagulase-negative staphy-
lococci (CoNS), beta-hemolytic streptococci, and Streptococcus pneumoniae (99.3% susceptible), with MIC90 values of 0.25, 0.12,
<0.06, and 0.5g/ml, respectively. Ceftobiprole was active against methicillin-resistant S. aureus (MRSA) (98.3% susceptible)
and methicillin-resistant CoNS, having a MIC90 of 2g/ml. Ceftobiprole was active against Enterococcus faecalis (MIC50/90, 0.5/4
g/ml) but not against most Enterococcus faecium isolates. Ceftobiprole was very potent against the majority of Enterobacteria-
ceae (87.3% susceptible), with>80% inhibited at<0.12g/ml. The potency of ceftobiprole against Pseudomonas aeruginosa
(MIC50/90, 2/>8g/ml; 64.6% at MIC values of<4g/ml) was similar to that of ceftazidime (MIC50/90, 2/>16g/ml; 75.4% sus-
ceptible), but limited activity was observed against Acinetobacter spp. and Stenotrophomonas maltophilia. High activity was also
observed against all Haemophilus influenzae (MIC90,<0.06 g/ml) and Moraxella catarrhalis (MIC50/90,<0.06/0.25 g/ml)
isolates. Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of con-
temporary pathogens.
Ceftobiprole medocaril (BAL5788, formerly Ro-65-5788) is theprodrug form of ceftobiprole (BAL9141, formerly Ro-63-9141),
which is an extended-spectrum anti-methicillin-resistant Staphylo-
coccus aureus (anti-MRSA) parenteral cephalosporin with potent
activity against Gram-positive and -negative bacterial pathogens.
Ceftobiprole has been evaluated in several phase III clinical trials
focusing on skin and skin structure infections (SSSI) (1, 2), com-
munity-acquired pneumonia (CAP) requiring hospitalization
(3), and hospital-acquired pneumonia (HAP), including ventila-
tor-associated pneumonia (VAP) (4), and has recently obtained
regulatory approval in Europe for the treatment of hospital-ac-
quired pneumonia (excluding ventilator-associated pneumonia)
and community-acquired pneumonia in adults. Ceftobiprole is
relatively stable toward AmpC -lactamases and has a strong af-
finity for penicillin binding proteins (PBPs), including PBP 2A,
which mediates resistance to -lactams in MRSA and methicillin
(oxacillin)-resistant coagulase-negative staphylococci (CoNS)
(5). PBP assay experiments have confirmed the remarkably high
affinity of ceftobiprole to PBP 2A and showed that this-lactam in
low concentrationswas also able to saturate PBPs 1, 3, and 4, a new
property not shared by other -lactams (6). Ceftobiprole also has
high affinity against Streptococcus pneumoniae PBP 2x in penicil-
lin-resistant and ceftriaxone-resistant strains and retains good in
vitro activity against them (7, 8). In time-kill analysis, ceftobiprole
was bactericidal against community-acquired and hospital-ac-
quired MRSA strains (9).
Ceftobiprole also displays potent activity against Enterobacte-
riaceae andPseudomonas aeruginosa isolates that is similar to those
of advanced-generation cephalosporins such as cefepime (10–13).
In addition, ceftobiprole has demonstrated activity against Hae-
mophilus influenzae, Moraxella catarrhalis (7), and Enterococcus
faecalis (8). These characteristics make ceftobiprole an attractive
therapeutic candidate, given its broad spectrum (includingMRSA
and penicillin-resistant S. pneumoniae) and its potent bactericidal
action.
The objective of the current study was to examine the suscep-
tibility profiles and antibiograms of ceftobiprole and comparator
agents tested by a standardized reference methodology against
60,084 clinical isolates collected during the years 2005 through
2010 from European region medical centers, Turkey, and Israel.
MATERIALS AND METHODS
Bacterial strains tested. From the ceftobiprole SENTRYAntibiotic Sur-
veillance Program in Europe (2005 to 2010), a total of 60,084 nondu-
plicate, consecutive clinical isolates were submitted from 33 medical
centers in the following countries (number of sites): Belgium (1),
France (5), Germany (4), Greece (2), Ireland (2), Israel (1), Italy (3),
Poland (1), Portugal (1), Russia (2), Spain (3), Sweden (2), Switzer-
land (1), Turkey (2), the United Kingdom (2), and Ukraine (1). All
organisms were isolated from documented infections, and only one
strain per patient infection episode was included in the surveillance
collection. The isolates were derived primarily from hospitalized pa-
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tients with bloodstream infections, SSSI, pneumonias, urinary tract
infections, and intra-abdominal infections, according to a common
surveillance design (14). Species identification was performed at the
participant medical center and confirmed at the monitoring labora-
tory (JMI Laboratories, North Liberty, IA, USA) using the Vitek 2
System (bioMérieux, Hazelwood, MO, USA), when necessary.
Susceptibility testingmethods.All isolates were tested by the Clinical
and Laboratory Standards Institute (CLSI) broth microdilution method
(M07-A9, 2012) (15) using validated commercially prepared panels
(Thermo Fisher Scientific, Cleveland, OH, USA) in cation-adjusted Mu-
eller-Hinton broth (with 5% lysed horse blood added for testing of fastid-
ious streptococci or Haemophilus test medium [HTM] for testing of H.
influenzae) against ceftobiprole and comparator antimicrobial agents.
Susceptibility interpretations were based upon the CLSI M100-S23 and
EUCAST breakpoints (16, 17) and the EUCAST breakpoints recently es-
tablished for ceftobiprole for S. aureus (susceptible,2 g/ml; resistant,
2 g/ml), S. pneumoniae (susceptible,0.5 g/ml; resistant,0.5 g/
ml), and Enterobacteriaceae (susceptible, 0.25 g/ml; resistant, 0.25
g/ml) and non-species-specific breakpoints (susceptible,4 g/ml; re-
sistant, 4 g/ml) (18). Concurrent testing of ATCC quality control
(QC) strains included S. aureus ATCC 29213, E. faecalis ATCC 29212,
Escherichia coli ATCC 25922 and ATCC 35218, P. aeruginosa ATCC
27853, S. pneumoniae ATCC 49619, and H. influenzae ATCC 49247. All
QC results were observed to be within published limits (16, 19).
RESULTS
Ceftobiprole activity against staphylococci. Ceftobiprole was
very active against 15,426 S. aureus isolates (MIC50/90, 0.5/1 g/
ml; all MIC results at4g/ml; 99.5% susceptible) (Tables 1 and
2). Ceftobiprole (MIC50/90, 0.25/0.5 g/ml) was at least 16-fold
more potent than ceftriaxone (MIC50/90, 4/8 g/ml) when
tested against methicillin-susceptible S. aureus (MSSA) (Table 2).
All S. aureus isolates were susceptible to vancomycin (MIC50/90,
1/1 g/ml), and 99.9% of isolates were susceptible to linezolid
(MIC50/90, 1/2 g/ml), tigecycline (MIC50/90, 0.12/0.25 g/ml),
and daptomycin (MIC50/90, 0.25/0.5 g/ml) (Table 2). Among
11,279 MSSA isolates, the ceftobiprole susceptibility rate was
100.0% (Table 2).Overall, 4,147 (26.9%) isolates wereMRSA, and
ceftobiprole was very active against most strains (MIC50/90, 1/2
g/ml; 98.3% susceptible), with a potency most similar
to those of vancomycin (MIC50/90, 1/1 g/ml) and linezolid
(MIC50/90, 1/2 g/ml) (Table 2). High resistance rates among
MRSA were observed for levofloxacin (88.6%), erythromycin
(68.0%), and clindamycin (35.6/35.8%) (CLSI/EUCAST criteria),
with lower rates observed for gentamicin (21.4/23.8%) and tetra-
cycline (14.7/16.3%), while trimethoprim-sulfamethoxazole re-
sistance was minimal (2.7%) (Table 2).
TABLE 1 Frequency of occurrence and cumulative percent distribution of ceftobiprole MICs for all European organisms tested (2005 to 2010)
Organism(s) (no. of isolates tested)
No. (cumulative %) of isolates inhibited at a ceftobiprole MIC (g/ml) of:
MIC50 MIC900.06 0.12 0.25 0.5 1 2 4 8 8
Gram-positive bacteria
Staphylococcus aureus (15,426) 30 (0.2) 163 (1.3) 6,338 (42.3) 5,302 (76.7) 2,372 (92.1) 1,149 (99.5) 72 (100.0) 0.5 1
MSSA (11,279) 30 (0.3) 162 (1.7) 6,316 (57.7) 4,738 (99.7) 29 (100.0) 4 (100.0) 0.25 0.5
MRSA (4,147) 0 (0.0) 1 (0.0) 22 (0.6) 564 (14.2) 2,343 (70.7) 1,145 (98.3) 72 (100.0) 1 2
Coagulase-negative staphylococci
(5,563)
236 (4.2) 650 (15.9) 624 (27.1) 1,191 (48.6) 1,757 (80.1) 721 (93.1) 383 (100.0) 1 (100.0) 1 2
Methicillin-susceptible CoNS (1,317) 209 (15.9) 616 (62.6) 455 (97.2) 35 (99.8) 2 (100.0) 0.12 0.25
Methicillin-resistant CoNS (4,246) 27 (0.6) 34 (1.4) 169 (5.4) 1,156 (32.6) 1,755 (74.0) 721 (91.0) 383 (100.0) 1 (100.0) 1 2
Streptococcus pneumoniae (4,443) 3,428 (77.2) 109 (79.6) 369 (87.9) 508 (99.3) 23 (99.9) 6 (100.0) 0.06 0.5
Penicillin susceptible (4,223) 3,427 (81.2) 108 (83.7) 356 (92.1) 325 (99.8) 7 (100.0) 0.06 0.25
Penicillin nonsusceptible (217) 1 (0.5) 1 (0.9) 13 (6.8) 183 (90.0) 16 (97.3) 6 (100.0) 0.5 0.5
Penicillin intermediate (209) 1 (0.5) 1 (1.0) 13 (7.2) 179 (92.8) 12 (98.6) 3 (100.0) 0.5 0.5
Penicillin resistant (11) 0 (0.0) 0 (0.0) 0 (0.0) 4 (36.4) 4 (72.7) 3 (100.0) 1 2
Ceftriaxone nonsusceptible (202) 0 (0.0) 1 (0.5) 4 (2.5) 168 (85.6) 23 (97.0) 6 (100.0) 0.5 1
Ceftriaxone resistant (20) 0 (0.0) 0 (0.0) 0 (0.0) 3 (15.0) 12 (75.0) 5 (100.0) 1 2
Beta-hemolytic streptococci (2,981) 2,957 (99.2) 22 (99.9) 2 (100.0) 0.06 0.06
S. pyogenes (1,170) 1,167 (99.7) 2 (99.9) 1 (100.0) 0.06 0.06
S. agalactiae (1,227) 1,222 (99.6) 4 (99.9) 1 (100.0) 0.06 0.06
Viridans group streptococci (1,264) 929 (73.5) 173 (87.2) 65 (92.3) 23 (94.1) 20 (95.7) 22 (97.5) 9 (98.2) 4 (98.5) 19 (100.0)  0.06 0.25
Enterococcus spp. (6,395) 37 (0.6) 476 (8.0) 883 (21.8) 1,321 (42.5) 374 (48.3) 634 (58.2) 401 (64.5) 145 (66.8) 2,124 (100.0) 2 8
Enterococcus faecalis (3,968) 31 (0.8) 466 (12.5) 860 (34.2) 1,259 (65.9) 316 (73.9) 527 (87.2) 348 (95.9) 118 (98.9) 43 (100.0) 0.5 4
Enterococcus faecium (2,222) 0 (0.0) 5 (0.2) 3 (0.4) 4 (0.5) 24 (1.6) 71 (4.8) 45 (6.8) 16 (7.6) 2,054 (100.0) 8 8
Other enterococci (205) 6 (2.9) 5 (5.4) 20 (15.1) 58 (43.4) 34 (60.0) 36 (77.6) 8 (81.5) 11 (86.8) 27 (100.0) 1 8
Gram-negative bacteria
Enterobacteriaceae (17,480) 13,398 (76.6) 803 (81.2) 374 (83.4) 243 (84.8) 159 (85.7) 154 (86.6) 132 (87.3) 99 (87.9) 2,118 (100.0) 0.06 8
Escherichia coli (9,609) 8,194 (85.3) 272 (88.1) 100 (89.1) 48 (89.6) 26 (89.9) 26 (90.2) 24 (90.4) 20 (90.6) 899 (100.0) 0.06 2
ESBLa phenotype (1,089) 73 (6.7) 16 (8.2) 23 (10.3) 12 (11.4) 14 (12.7) 19 (14.4) 24 (16.6) 19 (18.4) 889 (100.0) 8 8
Non-ESBL phenotype (8,520) 8,121 (95.3) 256 (98.3) 77 (99.2) 36 (99.7) 12 (99.8) 7 (99.9) 0 (99.9) 1 (99.9) 10 (100.0) 0.06 0.06
Klebsiella pneumoniae (2,625) 1,760 (67.0) 93 (70.6) 46 (72.3) 32 (73.6) 27 (74.6) 16 (75.2) 10 (75.6) 16 (76.2) 625 (100.0) 0.06 8
ESBL phenotype (703) 14 (2.0) 7 (3.0) 7 (4.0) 7 (5.0) 16 (7.3) 16 (9.5) 10 (11.0) 16 (13.2) 610 (100.0) 8 8
Non-ESBL phenotype (1,922) 1,746 (90.8) 86 (95.3) 39 (97.4) 25 (98.7) 11 (99.2) 0 (99.2) 0 (99.2) 0 (99.2) 15 (100.0) 0.06 0.06
Proteus mirabilis (733) 666 (90.9) 13 (92.6) 7 (93.6) 4 (94.1) 3 (94.5) 1 (94.7) 0 (94.7) 3 (95.1) 36 (100.0) 0.06 0.06
Enterobacter spp. (1,909) 1,237 (64.8) 118 (71.0) 54 (73.8) 42 (76.0) 35 (77.8) 77 (81.9) 79 (86.0) 46 (88.4) 221 (100.0) 0.06 8
Citrobacter spp. (414) 301 (72.7) 15 (76.3) 6 (77.8) 14 (81.2) 23 (86.7) 20 (91.5) 5 (92.8) 4 (93.7) 26 (100.0) 0.06 2
Serratia spp. (711) 405 (57.0) 140 (76.7) 51 (83.8) 46 (90.3) 23 (93.5) 8 (94.7) 7 (95.6) 4 (96.2) 27 (100.0) 0.06 0.5
Indole-positive Proteus spp. (479) 357 (74.5) 2 (74.9) 2 (75.4) 2 (75.8) 0 (75.8) 0 (75.8) 1 (76.0) 3 (76.6) 112 (100.0) 0.06 8
Pseudomonas aeruginosa (3,434) 2 (0.1) 4 (0.2) 11 (0.5) 113 (3.8) 826 (27.8) 806 (51.3) 458 (64.6) 489 (78.9) 725 (100.0) 2 8
Ceftazidime susceptible (2,588) 2 (0.1) 3 (0.2) 11 (0.6) 112 (4.9) 812 (36.3) 761 (65.7) 327 (78.4) 325 (90.9) 235 (100.0) 2 8
Ceftazidime nonsusceptible (846) 0 (0.0) 1 (0.1) 0 (0.1) 1 (0.2) 14 (1.9) 45 (7.2) 131 (22.7) 164 (42.1) 490 (100.0) 8 8
Acinetobacter spp. (1,146) 59 (5.1) 37 (8.4) 96 (16.8) 85 (24.2) 45 (28.1) 18 (29.7) 12 (30.7) 8 (31.4) 786 (100.0) 8 8
Stenotrophomonas maltophilia (420) 0 (0.0) 1 (0.2) 0 (0.2) 0 (0.2) 0 (0.2) 0 (0.2) 0 (0.2) 2 (0.7) 417 (100.0) 8 8
Haemophilus influenzae (2,052) 1,965 (95.8) 76 (99.5) 8 (99.9) 3 (100.0) 0.06 0.06
Moraxella catarrhalis (200) 107 (53.5) 70 (88.5) 20 (98.5) 3 (100.0) 0.06 0.25
a ESBL, extended-spectrum -lactamase.
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TABLE 2 Antimicrobial activities of ceftobiprole and comparator agents when tested against bacterial isolates from European medical centers (2005
to 2010)
Organism (no. of isolates tested) and antimicrobial agent
MIC
% of isolates
susceptible/intermediate/resistanta
MIC50 MIC90 Range CLSI EUCAST
S. aureus (15,426)
Ceftobiprole 0.5 1 0.06–4 —b/—/— 99.5/0.0/0.5
Oxacillin 0.5 2 0.25–2 73.1/0.0/26.9 73.1/0.0/26.9
Cefepime 2 16 0.12–16 73.1/0.0/26.9 73.1/0.0/26.9
Ceftriaxone 4 8 0.25–8 73.1/0.0/26.9 73.1/0.0/26.9
Imipenem 0.12 8 0.12–8 73.1/0.0/26.9 73.1/0.0/26.9
Clindamycin 0.25 2 0.25–2 88.6/0.1/11.3 88.1/0.5/11.4
Erythromycin 0.25 2 0.25–2 70.5/0.9/28.6 71.0/0.3/28.7
Daptomycin 0.25 0.5 0.06–2 99.9/—/— 99.9/0.0/0.1
Gentamicin 2 2 2–8 92.5/0.5/7.0 91.9/0.0/8.1
Levofloxacin 0.5 4 0.5–4 71.6/0.6/27.8 71.6/0.6/27.8
Linezolid 1 2 0.12–8 99.9/0.0/0.1 99.9/0.0/0.1
Tetracycline 2 2 2–8 91.7/0.6/7.7 91.4/0.0/8.6
Tigecyclinec 0.12 0.25 0.03–1 99.9/—/— 99.9/0.0/0.1
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 99.0/0.0/1.0 99.0/0.1/1.0
Vancomycin 1 1 0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Oxacillin-susceptible S. aureus (11,279)
Ceftobiprole 0.25 0.5 0.06–2 —/—/— 100.0/0.0/0.0
Cefepime 2 4 0.12–16 100.0/0.0/0.0 100.0/0.0/0.0
Ceftriaxone 4 4 0.25–8 100.0/0.0/0.0 100.0/0.0/0.0
Imipenem 0.12 0.12 0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Clindamycin 0.25 0.25 0.25–2 97.5/0.1/2.4 97.1/0.4/2.5
Erythromycin 0.25 2 0.25–2 85.1/0.8/14.1 85.4/0.4/14.2
Daptomycin 0.25 0.5 0.06–1 100.0/—/— 100.0/0.0/0.0
Gentamicin 2 2 2–8 98.1/0.2/1.7 97.7/0.0/2.3
Levofloxacin 0.5 0.5 0.5–4 94.1/0.4/5.5 94.1/0.4/5.5
Linezolid 1 2 0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Tetracycline 2 2 2–8 94.5/0.4/5.1 94.2/0.1/5.8
Tigecyclinec 0.12 0.25 0.03–0.5 100.0/—/— 100.0/0.0/0.0
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 99.6/0.0/0.4 99.6/0.1/0.4
Vancomycin 1 1 0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Oxacillin-resistant S. aureus (4,147)
Ceftobiprole 1 2 0.12–4 —/—/— 98.3/0.0/1.7
Clindamycin 0.25 2 0.25–2 64.2/0.2/35.6 63.6/0.6/35.8
Erythromycin 2 2 0.25–2 30.9/1.1/68.0 31.6/0.4/68.0
Daptomycin 0.25 0.5 0.06–2 99.9/—/— 99.9/0.0/0.1
Gentamicin 2 8 2–8 77.2/1.4/21.4 76.2/0.0/23.8
Levofloxacin 4 4 0.5–4 10.4/1.0/88.6 10.4/1.0/88.6
Linezolid 1 2 0.25–8 99.9/0.0/0.1 99.9/0.0/0.1
Tetracycline 2 8 2–8 84.0/1.3/14.7 83.6/0.1/16.3
Tigecyclinec 0.12 0.25 0.03–1 99.9/—/— 99.9/0.0/0.1
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 97.3/0.0/2.7 97.3/0.0/2.7
Vancomycin 1 1 0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Coagulase-negative staphylococci (5,563)d
Ceftobiprole 1 2 0.06–8 —/—/— —/—/—
Oxacillin 2 2 0.25–2 23.7/0.0/76.3 23.7/0.0/76.3
Cefepime 4 16 0.12–16 23.7/0.0/76.3 23.7/0.0/76.3
Ceftriaxone 8 8 0.25–8 23.7/0.0/76.3 23.7/0.0/76.3
Imipenem 0.25 8 0.12–8 23.7/0.0/76.3 23.7/0.0/76.3
Clindamycin 0.25 2 0.25–2 71.6/1.0/27.4 69.1/2.5/28.4
Erythromycin 2 2 0.25–2 36.3/0.3/63.4 36.4/0.2/63.4
Daptomycin 0.25 0.5 0.06–4 99.8/—/— 99.8/0.0/0.2
Gentamicin 2 8 2–8 58.8/8.2/33.0 52.2/0.0/47.8
Levofloxacin 4 4 0.5–4 42.3/4.8/52.9 42.3/4.8/52.9
Linezolid 1 1 0.12–8 99.8/0.0/0.2 99.8/0.0/0.2
Tetracycline 2 8 2–8 84.4/1.4/14.2 79.8/1.4/18.8
Tigecyclinec 0.12 0.25 0.03–0.5 —/—/— 100.0/0.0/0.0
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 60.9/0.0/39.1 60.9/1.8/37.3
Vancomycin 1 2 0.12–4 100.0/0.0/0.0 100.0/0.0/0.0
Enterococcus faecalis (3,968)
Ceftobiprole 0.5 4 0.06–8 —/—/— —/—/—
Ampicillin 1 2 1–16 99.6/0.0/0.4 99.4/0.2/0.4
Daptomycin 1 1 0.06–4 100.0/—/— —/—/—
Levofloxacin 1 4 0.5–4 65.4/0.6/34.0 —/—/—
Linezolid 1 2 0.12–8 99.8/0.1/0.1 99.8/0.1/0.1
Tigecyclinec 0.12 0.25 0.03–1 99.9/—/— 99.9/0.1/0.1
(Continued on following page)
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TABLE 2 (Continued)
Organism (no. of isolates tested) and antimicrobial agent
MIC
% of isolates
susceptible/intermediate/resistanta
MIC50 MIC90 Range CLSI EUCAST
Teicoplanin 2 2 2–8 99.1/0.1/0.9 99.0/0.0/1.0
Vancomycin 1 2 0.25–16 98.7/0.1/1.2 98.7/0.0/1.3
Enterococcus faecium (2,222)
Ceftobiprole 8 8 0.12–8 —/—/— —/—/—
Ampicillin 8 8 1–8 7.1/0.0/92.9 6.4/0.7/92.9
Daptomycin 2 2 0.06–4 100.0/—/— —/—/—
Levofloxacin 4 4 0.5–4 12.7/4.5/82.8 —/—/—
Linezolid 1 2 0.25–8 99.6/0.2/0.2 99.8/0.0/0.2
Tigecyclinec 0.06 0.12 0.03–0.5 99.9/0.1/— 99.9/0.1/0.0
Teicoplanin 2 8 2–8 81.0/1.5/17.5 79.8/0.0/20.2
Vancomycin 1 16 0.12–16 75.3/1.5/23.2 75.3/0.0/24.7
Streptococcus pneumoniae (4,443)
Ceftobiprole 0.06 0.5 0.06–2 —/—/— 99.3/0.0/0.7
Penicilline 0.03 2 0.03–4 95.0/4.8/0.2 —/—/—
Penicillinf 0.03 2 0.03–4 71.1/12.0/16.9 71.1/23.9/5.0
Amoxicillin-clavulanate 1 2 1–16 93.9/3.1/3.0 —/—/—
Cefepime 0.12 1 0.12–16 95.7/4.0/0.3 95.7/4.0/0.3
Ceftriaxone 0.25 1 0.25–32 95.5/4.0/0.5 83.5/16.0/0.5
Erythromycin 0.25 2 0.25–2 69.0/0.4/30.6 69.0/0.4/30.6
Clindamycin 0.25 1 0.25–1 79.1/0.6/20.3 79.7/0.0/20.3
Levofloxacin 1 1 0.5–4 98.3/0.2/1.5 98.3/0.0/1.7
Linezolid 1 1 0.12–2 100.0/—/— 100.0/0.0/0.0
Tetracycline 2 8 2–8 74.4/1.2/24.4 74.4/0.1/25.6
Tigecyclinec 0.03 0.06 0.03–1 91.0/—/— —/—/—
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 70.2/11.0/18.8 77.1/4.1/18.8
Vancomycin 1 1 1–1 100.0/—/— 100.0/0.0/0.0
-Hemolytic streptococci (2,981)g
Ceftobiprole 0.06 0.06 0.06–0.25 —/—/— —/—/—
Penicillin 0.03 0.06 0.03–0.12 100.0/—/— 100.0/0.0/0.0
Cefepime 0.12 0.12 0.12–2 99.9/—/— 100.0/0.0/0.0
Ceftriaxone 0.25 0.25 0.25–4 99.9/—/— 100.0/0.0/0.0
Clindamycin 0.25 0.25 0.25–2 91.9/0.5/7.6 92.4/0.0/7.6
Erythromycin 0.25 2 0.25–2 82.0/1.0/17.0 82.0/1.0/17.0
Daptomycin 0.06 0.25 0.06–0.5 100.0/—/— 100.0/0.0/0.0
Levofloxacin 0.5 1 0.5–4 99.6/0.0/0.4 95.6/4.0/0.4
Linezolid 1 1 0.25–2 100.0/—/— 100.0/0.0/0.0
Tetracycline 4 8 2–8 49.5/2.6/47.9 49.3/0.2/50.5
Tigecyclinec 0.03 0.06 0.03–0.5 99.9/—/— 99.9/0.1/0.0
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 —/—/— 99.0/0.4/0.6
Vancomycin 0.25 0.5 0.12–1 100.0/—/— 100.0/0.0/0.0
Viridans group streptococci (1,264)h
Ceftobiprole 0.06 0.25 0.06–8 —/—/— —/—/—
Penicillin 0.06 1 0.03–4 77.5/17.0/5.5 84.3/10.2/5.5
Cefepime 0.12 1 0.12–16 92.1/3.4/4.5 88.1/0.0/11.9
Ceftriaxone 0.25 1 0.25–8 92.2/3.2/4.6 88.8/0.0/11.2
Daptomycin 0.25 0.5 0.06–2 99.8/—/— —/—/—
Clindamycin 0.25 2 0.25–2 88.0/0.3/11.7 88.3/0.0/11.7
Erythromycin 0.25 2 0.25–2 61.6/2.2/36.2 —/—/—
Levofloxacin 1 2 0.5–4 96.8/1.1/2.1 —/—/—
Linezolid 1 1 0.12–2 100.0/—/— —/—/—
Tetracycline 2 8 2–8 62.2/2.2/35.6 —/—/—
Tigecyclinec 0.03 0.06 0.03–0.5 99.9/—/— —/—/—
Vancomycin 0.5 1 0.12–1 100.0/—/— 100.0/0.0/0.0
Enterobacteriaceae (17,480)i
Ceftobiprole 0.06 8 0.06–8 —/—/— 83.4/0.0/16.6
Ampicillin 8 8 1–8 28.5/3.8/67.7 28.5/0.0/71.5
Amoxicillin-clavulanate 8 8 1–8 62.6/10.9/26.5 62.6/0.0/37.4
Piperacillin-tazobactam 2 32 0.5–64 88.0/5.9/6.1 84.3/3.7/12.0
Cefepime 0.5 2 0.5–16 93.1/1.6/5.3 88.2/3.5/8.3
Ceftazidime 1 16 1–16 87.6/1.8/10.6 83.5/4.1/12.4
Imipenem 0.25 1 0.12–8 94.4/3.8/1.8 98.2/1.4/0.4
Aztreonam 0.12 16 0.12–16 86.6/2.1/11.3 83.6/5.1/11.3
Colistin 0.5 4 0.5–4 —/—/— 87.3/0.0/12.7
Amikacin 4 4 4–32 98.5/0.8/0.7 96.9/1.6/1.5
Gentamicin 2 8 2–8 89.7/0.8/9.5 88.7/1.0/10.3
Levofloxacin 0.5 4 0.5–4 80.9/2.6/16.5 79.3/1.6/19.1
(Continued on following page)
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Ceftobiprole activity against 5,563 coagulase-negative staphy-
lococci (CoNS) was similar to that found against MRSA and re-
flects the greater proportion ofCoNS than of S. aureus isolates that
were oxacillin resistant (76.3% versus 26.9%) (Table 1). One no-
table difference is the much higher overall rate of trimethoprim-
sulfamethoxazole resistance observed for CoNS (39.1%) than for
S. aureus (1.0%) (Table 2).
Ceftobiprole activity against enterococci. Ceftobiprole dem-
onstrated good activity against 3,968 E. faecalis isolates (MIC50/90,
0.5/4g/ml) but was not active against 2,222 Enterococcus faecium
TABLE 2 (Continued)
Organism (no. of isolates tested) and antimicrobial agent
MIC
% of isolates
susceptible/intermediate/resistanta
MIC50 MIC90 Range CLSI EUCAST
Tetracycline 2 8 2–8 62.0/3.1/34.9 —/—/—
Tigecyclinec 0.25 1 0.03–4 98.7/1.2/0.1 95.0/3.7/1.3
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 71.9/0.0/28.1 71.9/22.4/5.7
Acinetobacter spp. (1,146)j
Ceftobiprole 8 8 0.06–8 —/—/— —/—/—
Cefepime 16 16 0.12–16 36.5/14.1/49.4 —/—/—
Ceftazidime 16 16 1–16 29.4/7.5/63.1 —/—/—
Piperacillin-tazobactam 64 64 0.5–64 34.3/0.0/65.7 —/—/—
Imipenem 2 8 0.12–8 53.9/2.6/43.5 50.7/5.8/43.5
Aztreonam 16 16 0.12–16 8.2/15.9/75.9 —/—/—
Colistin 0.5 1 0.5–4 98.7/0.0/1.3 98.7/0.0/1.3
Amikacin 32 32 4–32 42.7/3.6/53.7 40.5/2.2/57.3
Gentamicin 8 8 2–8 35.8/3.2/61.0 35.8/0.0/64.2
Levofloxacin 4 4 0.5–4 31.8/8.7/59.5 29.8/2.0/68.2
Tetracycline 8 8 2–8 38.6/6.1/55.3 —/—/—
Trimethoprim-sulfamethoxazole 2 2 0.5–2 37.0/0.0/63.0 37.0/53.7/9.3
Pseudomonas aeruginosa (3,434)
Ceftobiprole 2 8 0.06–8 —/—/— 64.6k/—/35.4
Cefepime 4 16 0.12–16 78.6/11.7/9.7 78.6/0.0/21.4
Ceftazidime 2 16 1–16 75.4/5.2/19.4 75.4/0.0/24.6
Piperacillin-tazobactam 8 64 0.5–64 72.4/11.1/16.5 72.4/0.0/27.6
Imipenem 2 8 0.12–8 70.2/4.8/25.0 75.0/7.8/17.2
Aztreonam 8 16 0.12–16 66.6/13.7/19.7 3.4/76.9/19.7
Colistin 1 2 0.5–4 99.5/0.3/0.2 99.5/0.0/0.5
Amikacin 4 16 4–32 91.2/3.3/5.5 86.2/5.0/8.8
Gentamicin 2 8 2–8 78.8/3.1/18.1 78.8/0.0/21.2
Levofloxacin 0.5 4 0.5–4 69.2/5.7/25.1 62.0/7.2/30.8
a Criteria as published by the CLSI (2013) (16) and EUCAST (2013) (17) and the EUCAST breakpoints recently established for ceftobiprole for S. aureus (susceptible,2 g/ml;
resistant,2 g/ml), S. pneumoniae (susceptible,0.5 g/ml; resistant,0.5 g/ml), and Enterobacteriaceae (susceptible,0.25 g/ml; resistant,0.25 g/ml) and non-species-
specific breakpoints (susceptible,4 g/ml; resistant,4 g/ml) (18).
b —, no breakpoint has been established.
c U.S. FDA breakpoints (26) were applied as CLSI criteria.
d Includes S. auricularis (16 strains), S. capitis (201 strains), S. caprae (six strains), S. carnosus (one strain), S. chromogenes (four strains), S. cohnii (12 strains), S. epidermidis (2,673
strains), S. haemolyticus (467 strains), S. hominis (492 strains), S. intermedius (six strains), S. lentus (three strains), S. lugdunensis (92 strains), S. saprophyticus (67 strains), S.
schleiferi (nine strains), S. sciuri (12 strains), S. simulans (25 strains), S. succinus (one strain), S. warneri (115 strains), S. xylosus (79 strains), Staphylococcus of undetermined species
(two strains), and coagulase-negative staphylococci of undetermined species (1,280 strains).
e Criteria as published by the CLSI (2013) (16) for “penicillin parenteral (nonmeningitis).”
f Criteria as published by the CLSI (2013) (16) for “penicillin (oral penicillin V).”
g Includes S. dysgalactiae (126 strains), S. equi (three strains), S. equisimilis (13 strains), S. pyogenes (1,170 strains), S. agalactiae (1,227 strains), group C Streptococcus (108 strains),
group F Streptococcus (nine strains), group G Streptococcus (320 strains), and beta-hemolytic streptococci of undetermined species (five strains).
h Includes S. acidominimus (four strains), S. alactolyticus (one strain), S. anginosus (155 strains), S. anginosus group (57 strains), S. bovis group (103 strains), S. canis (one strain), S.
constellatus (53 strains), S. equinus (eight strains), S. gallolyticus (22 strains), S. gordonii (12 strains), S. infantis (one strain), S. intermedius (27 strains), S. mitis group (218 strains), S.
mutans (nine strains), S. oralis (134 strains), S. parasanguinis (39 strains), S. porcinus (one strain), S. salivarius (75 strains), S. sanguinis (75 strains), S. sobrinus (one strain), S.
thermophilus (two strains), S. uberis (three strains), S. vestibularis (17 strains), Streptococcus of undetermined species (19 strains), alpha-hemolytic streptococci of undetermined
species (19 strains), and viridans group streptococci of undetermined species (208 strains).
i Includes Citrobacter amalonaticus (three strains), C. braakii (11 strains), C. farmeri (two strains), C. freundii (236 strains), C. koseri (144 strains), C. sedlakii (one strain), C. youngae
(one strain), Enterobacter aerogenes (384 strains), E. amnigenus (nine strains), E. asburiae (five strains), E. cancerogenus (three strains), E. cloacae (1,385 strains), E. gergoviae (one
strain), E. hormaechei (two strains), E. intermedius (one strain), E. sakazakii (six strains), E. taylorae (one strain), Escherichia coli (9,609 strains), E. vulneris (one strain), Hafnia alvei
(31 strains), Klebsiella ornithinolytica (nine strains), K. oxytoca (743 strains), K. ozaenae (seven strains), K. planticola (one strain), K. pneumoniae (2,625 strains), K. terrigena (two
strains), Leclercia adecarboxylata (one strain), Morganella morganii (284 strains), Pantoea agglomerans (12 strains), Proteus mirabilis (733 strains), P. penneri (two strains), P. vulgaris
(93 strains), Providencia alcalifaciens (1 strain), P. rettgeri (16 strains), P. stuartii (35 strains), Rahnella aquatilis (one strain), Raoultella ornithinolytica (two strains), R. planticola
(one strain), Salmonella spp. (152 strains), Serratia fonticola (three strains), S. liquefaciens (31 strains), S. marcescens (637 strains), S. odorifera (four strains), S. plymuthica (six
strains), S. rubidaea (one strain), Shigella sonnei (two strains), Yersinia enterocolitica (four strains), Citrobacter of undetermined species (16 strains), Enterobacter of undetermined
species (112 strains), Escherichia of undetermined species (4 strains), Klebsiella of undetermined species (20 strains), Kluyvera of undetermined species (1 strain), Morganella of
undetermined species (1 strain), Pantoea of undetermined species (4 strains), Proteus of undetermined species (32 strains), Providencia of undetermined species (17 strains), and
Serratia of undetermined species (29 strains).
j Includes Acinetobacter baumannii (925 strains), A. calcoaceticus (19 strains), A. haemolyticus (eight strains), A. junii (three strains), A. lwoffii (58 strains), A. nosocomialis (one
strain), A. pittii (seven strains), A. radioresistens (one strain), A. ursingii (three strains), and Acinetobacter of undetermined species (121 strains).
k EUCAST non-species-specific breakpoint (18).
Farrell et al.
3886 aac.asm.org Antimicrobial Agents and Chemotherapy
isolates (MIC50,8g/ml) (Table 1). This pattern correlated best
to ampicillin susceptibility rates (Table 2). Vancomycin resistance
was low for E. faecalis (1.2/1.3%) (CLSI/EUCAST criteria) but
much higher forE. faecium (23.2/24.7%). Susceptibility rates of 99
to 100.0% were found for tigecycline, daptomycin, and linezolid
tested against both E. faecalis and E. faecium.
Ceftobiprole activity against S. pneumoniae. Ceftobiprole
was very active against S. pneumoniae, with MIC50 and MIC90
values of 0.06 and 0.5 g/ml, respectively. All isolates were in-
hibited at a ceftobiprole MIC of 2 g/ml or less, and 99.3% were
susceptible to ceftobiprole (Tables 1 and 2). Overall, penicillin
nonsusceptibility/resistancewere 28.9/16.9%byCLSI criteria (16)
(for oral penicillin V) and 28.9/5.0% by EUCAST criteria (17).
Furthermore, ceftriaxone nonsusceptibility/resistancewere 4.5/0.5%
byCLSI criteria but 16.5/0.5%by EUCAST criteria; ceftobiprole sus-
ceptibility was 85.6% against the 202 ceftriaxone-nonsusceptible
strains (Table 2). Erythromycin, clindamycin, tetracycline, and trim-
ethoprim-sulfamethoxazole resistances were 30.6, 20.3, 24.4, and
18.8%, respectively. All isolates were susceptible to linezolid (MIC90,
1g/ml), and themajority of isolateswere susceptible to levofloxacin
(98.3%) (Table 2).
Ceftobiprole activity against other streptococci.Ceftobiprole
was very active against all beta-hemolytic streptococci, including
1,170 isolates of S. pyogenes and 1,227 isolates of S. agalactiae, with
aMIC50 and aMIC90 at0.06g/ml. All isolates were inhibited at
a ceftobiprole MIC of 0.25 g/ml or less (Tables 1 and 2). Cefto-
biprole (MIC50/90, 0.06/0.25 g/ml) was at least 4-fold more
active than penicillin (MIC50/90, 0.06/1 g/ml; 22.5% nonsuscep-
tible) and ceftriaxone (MIC90, 1 g/ml) against 1,264 viridans
group streptococci (Table 2).
Ceftobiprole activity againstEnterobacteriaceae andnonfer-
mentative Gram-negative bacilli. The activity of ceftobiprole
against Enterobacteriaceae had a bimodal distribution, with 83.4%
of isolates being inhibited at aMIC of0.25g/ml (the EUCAST
susceptibility breakpoint) and 12.7% having MIC values of 8
g/ml (Table 1). Similar potencies and MIC distributions were
observed for ceftazidime, cefepime, and ceftriaxone (data not
shown). This pattern, shown for all cephalosporin agents tested, is
a reflection of their limited activity against extended-spectrum
-lactamase (ESBL) phenotype strains of E. coli (11.3%) andKleb-
siella spp. (26.8%). Ceftobiprole potency against P. aeruginosa
(MIC50/90, 2/8 g/ml; 64.6% susceptible by the EUCAST non-
species-specific susceptibility breakpoint of 4 g/ml) was similar
to those of cefepime (MIC50/90, 4/16 g/ml; 78.6% susceptible)
and ceftazidime (MIC50/90, 2/16g/ml; 75.4% susceptible) (Ta-
ble 2). Ceftobiprole had limited activity against Acinetobacter spp.
(MIC50, 8 g/ml) and Stenotrophomonas maltophilia (MIC50,
8 g/ml) (Table 1).
Ceftobiprole activity against H. influenzae and M. catarrha-
lis. Ceftobiprole was the most potent (MIC90, 0.06 g/ml) an-
timicrobial agent tested against H. influenzae, inhibiting all iso-
lates at 0.5 g/ml (Table 1). Ceftobiprole was also very active
against M. catarrhalis, inhibiting with MIC50/90 values of 0.06/
0.25 g/ml, and all isolates were inhibited at MIC values of0.5
g/ml (Table 1).
DISCUSSION
HAP is associatedwith significantmortality and has been reported
to account for 25% of all infections in intensive care units (20,
21). Increasing multidrug resistance (MDR) has complicated em-
pirical therapy for patients with HAP and VAP, especially in pa-
tients with risk factors for MDR pathogens, often necessitating a
combination therapy approach (22). It has been recommended
thatmonotherapy should be usedwhenever possible to reduce the
risk of MDR development and adverse outcomes (22). CAP is a
significant cause of morbidity and mortality in developed coun-
tries, especially in the elderly, with up to 60% of patients requiring
hospitalization (23, 24). Resistance among the CAP pathogens is
increasing and of major concern; an analysis of pneumococcal
resistance rates in the United States spanning the years 1998 to
2009 demonstrated remarkable increases in nonsusceptibility to
commonly used -lactam agents (25).
In this very large (60,084 isolates) and longitudinal (2005 to
2010) European antimicrobial resistance surveillance study, cefto-
biprole showed broad-spectrum activity against Gram-positive
and Gram-negative pathogens causative of HAP and CAP. Cefto-
biprole demonstrated high potency against staphylococci, includ-
ing MRSA and methicillin-resistant CoNS. Ceftobiprole was also
very potent against all beta-hemolytic and viridans streptococci
and demonstrated activity against nearly all E. faecalis isolates but
not E. faecium. The majority of Enterobacteriaceae (non-ESBL
producing) were also inhibited by ceftobiprole, an activity most
like those of cefepime, ceftriaxone, and ceftazidime. Activity
against P. aeruginosa (64.6% susceptible by the EUCAST non-
species-specific susceptibility breakpoint of 4 g/ml) was lower
than but similar to those of cefepime (78.6% susceptible) and
ceftazidime (75.4% susceptible). Ceftobiprole had more limited
activity against Acinetobacter spp., S. maltophilia, and ESBL phe-
notypes of Enterobacteriaceae, as noted with other marketed
broad-spectrum cephalosporins.
Ceftobiprole continues to demonstrate high potency against
the causative agents of CAP, with 99.3% of 4,443 S. pneumoniae
isolates testing susceptible, as well as 2,052 strains ofH. influenzae
inhibited at MIC values of 0.5 g/ml and 200 strains of M.
catarrhalis inhibited at MIC values of 0.5 g/ml. Ceftobiprole
was especially potent against penicillin-susceptible (MIC,2 g/
ml) strains of S. pneumoniae, which represented 95.0% of all iso-
lates, and potencies (although lower) were retained against peni-
cillin-resistant and ceftriaxone-resistant strains.
In summary, ceftobiprole exhibited excellent coverage of
Gram-positive pathogens, includingMRSA, andhas a spectrumof
activity against Gram-negative bacilli similar to those of third-
generation and fourth-generation cephalosporins consistently
over a period of 6 years. These in vitro results from an extensive
European surveillance study evaluating 60,084 organisms confirm
a large volume of earlier reports on the broad spectrum of activity
of ceftobiprole and hence demonstrate its potential to be utilized
as a single agent for the empirical therapy of pneumonia. Clinical
data from patients with pneumonia enrolled in large phase III
studies have demonstrated that ceftobiprole medocaril is nonin-
ferior to the combination of high-dose ceftazidime and linezolid
for the treatment of HAP (excluding VAP) (4) and noninferior to
high-dose ceftriaxone with or without linezolid for the treatment
of CAP requiring hospitalization (3). Ceftobiprole offers a num-
ber of advantages in potency, spectrum, and -lactamase stability
compared to currently marketed third-generation cephems and
other -lactams, especially with its enhanced coverage of MDR S.
aureus and CoNS, including methicillin-resistant strains.
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